Table 3. Hazard ratios for pravastatin compared to usual care using intention-to-treat, as-treated, and as-treated adjusted for baseline and time varying covariates*.
| eGFR group at baseline | Intent to treat | As-treated | As-treated, adjusted* | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | HR (95% CI) | p | n | HR (95% CI) | p | n | HR (95% CI) | p | |
| Mortality | |||||||||
| Total | 10,145 | 1.01 (0.91 – 1.13) | 0.82 | 10,145 | 0.76 (0.68 – 0.85) | < 0.001 | 10,021 | 0.73 (0.65 – 0.82) | < 0.001 |
| 60+ | 8,583 | 1.01 (0.89 – 1.14) | 0.88 | 8,583 | 0.74 (0.59 – 0.92) | 0.007 | 8,473 | 0.75 (0.66 – 0.86) | < 0.001 |
| < 60 | 1,562 | 1.02 (0.83 – 1.27) | 0.83 | 1,562 | 0.78 (0.69 – 0.88) | < 0.001 | 1,548 | 0.69 (0.54 – 0.87) | 0.002 |
| CHD | |||||||||
| Total | 10,068 | 0.91 (0.79 – 1.05) | 0.20 | 10,068 | 0.84 (0.73 – 0.97) | 0.01 | 9,944 | 0.88 (0.76 – 1.02) | 0.09 |
| 60+ | 8,520 | 0.92 (0.78 – 1.07) | 0.28 | 8,520 | 0.85 (0.73 – 1.00) | 0.04 | 8,410 | 0.89 (0.76 – 1.05) | 0.18 |
| < 60 | 1,548 | 0.90 (0.67 – 1.20) | 0.47 | 1,548 | 0.82 (0.61 – 1.11) | 0.20 | 1,534 | 0.86 (0.62 – 1.18) | 0.35 |
| Combined CVD | |||||||||
| Total | 10,078 | 0.97 (0.89 – 1.05) | 0.43 | 10.078 | 0.95 (0.88 – 1.04) | 0.30 | 9,953 | 0.98 (0.90 – 1.07) | 0.70 |
| 60+ | 8,526 | 0.94 (0.86 – 1.03) | 0.19 | 8,526 | 0.93 (0.85 – 1.01) | 0.10 | 8,416 | 0.94 (0.85 – 1.03)** | 0.17 |
| < 60 | 1,552 | 1.09 (0.91 – 1.30) | 0.36 | 1,552 | 1.12 (0.93 – 1.34) | 0.23 | 1,537 | 1.18 (0.98 – 1.43)** | 0.08 |
CHD = coronary heart disease; CI = confidence interval; CVD = cardiovascular disease; GFR = glomerular filtration rate; HR = hazard ratio. *Lipid trial baseline variables: age, gender, aspirin use, history of coronary heart disease, diabetes, antihypertensive treatment group, body mass index, Black, and time-varying covariates (systolic blood pressure, diastolic blood pressure and total cholesterol); **p for eGFR × treatment group interaction = 0.03.